RBI
SUPN icon

Raiffeisen Bank International’s Supernus Pharmaceuticals SUPN Stock Holding History

Raiffeisen Bank International’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-671
Closed -$27K – 900
2025
Q2 		$21.1K Hold
671
– – ﹤0.01% 525
2025
Q1 		$22K Hold
671
– – ﹤0.01% 536
2024
Q4 		$24.7K Buy
+671
New +$23.6K ﹤0.01% 537

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raiffeisen Bank International's SUPN Position: Q3 2025 in Review

Raiffeisen Bank International sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 671 shares — an estimated $27K sold.

Raiffeisen Bank International first reported a position in SUPN in Q4 2024 and held it in 3 quarters. The position peaked at $24.7K in Q4 2024. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • Raiffeisen Bank International reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raiffeisen Bank International sold 671 Supernus Pharmaceuticals shares in Q3 2025, an estimated $27K.
  • Raiffeisen Bank International first reported a position in Supernus Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Raiffeisen Bank International's Supernus Pharmaceuticals position peaked at $24.7K in Q4 2024.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on Raiffeisen Bank International's 13F filing for Q3 2025, filed 10 Nov 2025.